Company Overview and News

12
Redfin: An Integrated Full-Service Real Estate Competitor

2018-10-13 seekingalpha
Redfin is expanding some of its exciting and innovative services that aren't widespread in the real estate industry.
RDFN Z

13
SoftBank bets $400 million on housing market startup Opendoor

2018-10-01 japantimes.co.jp - 1
Opendoor, which has already raised billions to buy homes over the internet, just landed another large investor: the SoftBank Vision Fund.
RDFN ZG Z LEN RLGY 9984 LEN.B SFTBF SFTBY

161
Tracking Chase Coleman's Tiger Global Portfolio - Q2 2018 Update

2018-09-05 seekingalpha - 9
The largest three positions are Spotify, Amazon.com, and JD.com, and they add up to ~30% of the portfolio.
RDFN BCS NOW HUYA REDU FPI CRM QSR.WI SOGO 83SF FEYE AMZN 83SK TWTR MELI SWCH TEAM PSTG COUP BILI CLDR MSFT JD FB FIT LC MDB DOCU NFLX APO ADBE DESP DBX OKTA QSR 47MC SHOP NETS TDG RUN ZTO MA PVTL AVLR V BKNG IQ ADSK FLT

 
Redfin to Present at Deutsche Bank Technology Conference

2018-08-29 globenewswire
SEATTLE, Aug. 29, 2018 (GLOBE NEWSWIRE) -- Redfin Corporation (NASDAQ: RDFN), the technology-powered residential real estate brokerage, today announced that Chief Financial Officer Chris Nielsen will present at the following investor conference:
RDFN

5
Redfin (RDFN) in Focus: Stock Moves 5.1% Higher

2018-08-21 zacks - 1
Redfin Corporation (RDFN - Free Report) was a big mover last session, as the company saw its shares rise more than 5% on the day. The move came on solid volume too with far more shares changing hands than in a normal session. This reverses the recent trend for the company as the stock is now down 26.3% in the past one-month time frame.
RDFN TOL MLNX CIG CIGI

 
Redfin: Housing Market Realities Are Weighing Down

2018-08-21 seekingalpha
Redfin's shares plummeted after reporting Q2 earnings, despite a beat to quarterly results on both the top and bottom lines.
RDFN

 
RDFN / Redfin Corp null

2018-08-16 sec.gov
begin 644 filename1.pdf M)5!$1BTQ+C4-)>+CS],-"C4P(# @;V)J#3P\+TQI;F5A
RDFN

 
RDFN / Redfin Corp null

2018-08-16 sec.gov
Document July 16, 2018 Securities and Exchange Commission
RDFN

 
RDFN / Redfin Corp null

2018-08-16 sec.gov
Document Redfin Corporation 1099 Stewart Street, Suite 600
RDFN

153
What Are Millennials Spending Money On? - Cramer's Mad Money (8/14/18)

2018-08-15 seekingalpha - 1
Stocks discussed on the in-depth session of Jim Cramer's Mad Money TV Program, Tuesday, August 14.
HD RDFN TPR RAD WBA KATE CVNA CVS AAP AET

48
Despite Earnings Beat, Redfin Stock Cannot Escape a Slowing Market

2018-08-15 investorplace - 1
Redfin (NASDAQ:RDFN) plunged in trading following earnings. The Seattle-based real estate brokerage company lost over 22.4% of its value despite beating earnings and revenue expectations. Fears of a real estate slowdown in key metro areas weighed on RDFN stock.
RDFN ZG AMZN Z

16
Continue To Avoid Redfin

2018-08-13 seekingalpha - 2
Revenue is slowing and net income and free cash are set to follow. This is the most expensive stock I've seen on a price to free cash flow basis.
RDFN FB ZG Z

 
RDFN / Redfin Corp / PRICE T ROWE ASSOCIATES INC /MD/ - null (Passive Investment)

2018-08-11 sec.gov
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1) Redfin Corp (Name of Issuer) COMMON STOCK (Title of Class of Securities) 75737F108 (CUSIP NUMBER) July 31, 2018 (Date of Event which Requires Filing of Statement) Check the appropriate box to designate the Rule pursuant to which this Schedule is filed: [x] Rule 13d - 1(b) Rule 13d - 1(c) Rule 13d - 1(d) 1.
RDFN

 
RDFN / Redfin Corp / PRICE T ROWE ASSOCIATES INC /MD/ - null (Passive Investment)

2018-08-11 sec.gov
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1) Redfin Corp (Name of Issuer) COMMON STOCK (Title of Class of Securities) 75737F108 (CUSIP NUMBER) July 31, 2018 (Date of Event which Requires Filing of Statement) Check the appropriate box to designate the Rule pursuant to which this Schedule is filed: [x] Rule 13d - 1(b) Rule 13d - 1(c) Rule 13d - 1(d) 1.
RDFN

 
Real Estate Weekly: Homebuilders Rally, REITs Decline As Earnings Season Concludes

2018-08-11 seekingalpha
US equity markets reversed earlier weekly gains on Friday amid a broader “flight to safety.” Investors fled emerging markets into safe-haven US Treasuries, sending the 10-Year yield below 2.90%.
RDFN PSA.A PSA PSAXZ

Related Articles

ALIM: Alimera Sciences Analysis and Research Report

2018-10-01 - Asif

Overview The following discussion and analysis should be read in conjunction with its unaudited interim condensed consolidated financial statements and the related notes that appear elsewhere in this quarterly report on Form 10-Q. This discussion contains forward-looking statements reflecting its current expectations that involve risks and uncertainties. Actual results may differ materially from those discussed in these forward-looking statements due to a number of factors, including those set forth in the section entitled “Risk Factors” in its most recent annual report on Form 10-K. For further information regarding forward-looking statements, please refer to the “Special Note Regarding Forward-Looking Statements and Projections” immediately after the index to this quarterly report on Form 10-Q. Alimera Sciences, Inc., and its subsidiaries (we or Alimera), is a pharmaceutical company that specializes in the commercialization and development of prescription ophthalmic pharma...

DMPI: DelMar Pharmaceuticals Analysis and Research Report

2018-09-25 - Asif

Background DelMar Pharmaceuticals, Inc. is a clinical stage drug development company with a focus on the treatment of cancer. The company's mission is to benefit patients and create shareholder value by developing and commercializing anti-cancer therapies for patients whose tumors exhibit features that make them resistant to, or unlikely to respond to, currently available therapies, particularly for orphan cancer indications where patients have failed, or are unlikely to respond to, currently available therapy. DelMar Pharmaceuticals is developing VAL-083, a novel, DNA-targeting agent, for the treatment of glioblastoma multiforme (“GBM”) and potentially other solid tumors, including ovarian cancer. VAL-083 is a first-in-class, DNA-targeting chemotherapeutic that demonstrated activity against a range of tumor types in prior Phase 1 and Phase 2 clinical studies sponsored by the US National Cancer Institute (“NCI”). The company's recent research has highlighted the opportunit...

RIGL: Rigel Pharmaceuticals Analysis and Research Report

2018-09-18 - Asif

Overview Rigel Pharmaceuticals is a biotechnology company dedicated to discovering, developing and providing novel small molecule drugs that significantly improve the lives of patients with immune and hematologic disorders, cancer and rare diseases. The company's pioneering research focuses on signaling pathways that are critical to disease mechanisms. The company's first FDA-approved product is TAVALISSE™ (fostamatinib disodium hexahydrate), an oral spleen tyrosine kinase (SYK) inhibitor, for the treatment of adult patients with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment. The company's current clinical programs include Phase 2 studies of fostamatinib in autoimmune hemolytic anemia and IgA nephropathy, and a Phase 1 study for its IRAK program. In addition, Rigel Pharmaceuticals has product candidates in development with partners BerGenBio AS, Daiichi Sankyo, and Aclaris Therapeutics. Since inception, Rigel Pharmaceuticals h...

CUSIP: 75737F108